You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a selective biosensor for detecting organophosphate exposure
SBC: NAGY CONSULTING Topic: N/ADESCRIPTION (provided by applicant): This SBIR project is in response to the call for the development of rapid and portable diagnostic tools for chemical threat exposure, suitable for use by emergency care providers in order to guide medical countermeasures. The broad objective of this proposal is to develop an extremely sensitive and selective biosensor device capable of detecting and discriminat ...
SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Anthrax Vaccine Formulations Combining PA/Spore Epitopes
SBC: LIGOCYTE PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Pulmonary anthrax, a rare but extremely severe form of anthrax, is initiated by phagocytosis of Bacillus anthracis spores by alveolar macrophages (AMs). The current, Protective Antigen (PA) based, vaccine requires sev
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Discovery of NaV1.7 Inhibitors for the Treatment of Pain
SBC: SITEONE THERAPEUTICS, INC. Topic: 105PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic pain, such as pain associated with chemotherapy-induced peripheral neuropathy, that targets an isoform of the voltage-gated sodium ion channel, NaV1.7. Voltage-gated sodium channels are involved in the transmission of nociceptive signals from their site of origin in ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Project isoPTE: isothermic post-traumatic epilepsy miRNA biomarker detection
SBC: FYR Diagnostics, LLC Topic: 999Project Summary Acquired epilepsy results from acute brain injury, such as traumatic brain injury (TBI). Acquired epilepsy is a major public health issue with inadequate treatment and diagnostic options. There are no biomarkers that assist in the prediction or diagnosis of acquired epilepsy. Project isoPTE will use two animal models of epilepsy to determine whether plasma microRNA (miRNA) biomarke ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis
SBC: INIMMUNE CORP Topic: NIAIDThe long term goal of this proposal is the development of an intranasal stand alone TLRagonist to treat allergic rhinitisUnlike antigen specific therapythis allergen independent approach will be broadly applicable to a vast array of allergens patients are exposed toSuch treatment would provide relief within hours of administrationproviding short term symptom controland has the potential to deliver ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
GROUP B STREPTOCOCCAL PEPTIDE MIMETIC VACCINE
SBC: LIGOCYTE PHARMACEUTICALS, INC. Topic: N/AGroup B streptococcus (GBS) causes invasive infections of newborns, pregnant women and adults with underlying medical conditions, such as diabetes or cancer. Despite antibiotic treatment, estimated case fatality rates of 5-20% in neonates and 15-32% in adults establish the prevention of GBS infections as a public health priority. Peptide immunogens that mimic the structure of GBS capsular polysach ...
SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
Artificial Accessory Cell Platform for Stem Cell Culture
SBC: RESODYN CORPORATION Topic: NIGMSDESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project will develop and demonstrate a broad-application prototype Artificial Accessory Cell that can be used as a supplement and/or replacement for cytokines for the directed differentiation of stem cells into desired lineages. While the technology is applicable to all types of stem cells for which some informati ...
SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Developing EXP-1801 as an imaging agent to quantify pain and analgesia
SBC: Expesicor Inc Topic: NINDSSummary Abstract There are currently no tools available that can objectively measure painHistoricallypain in humans has been measured using subjective ratings to determine presence and severityIn animal modelspain is measured by semi quantitative assays that rely on the observation of pain behaviorsThough usefulthe inherently subjective nature of these measures has hampered both research and treat ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Multiplex Fluorescent Dyes for Ultrasensitive Proteomics
SBC: ZDYE, LLC Topic: N/ADESCRIPTION (provided by applicant): This STTR proposal describes collaborative research between Zdye LLC and Montana State University (MSU) to synthesize and demonstrate innovative ultrasensitive, fluorescent dyes for multicolor (multiplex) detection in proteomics. The resulting "Zdyes" are designed for vastly improved quantitation of differential protein expression and changes in protein post-tr ...
SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options
SBC: Golden Helix, Inc. Topic: 172Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health